Robert Booth, Ph.D., has served on our Board of Directors since September 2022.

Dr. Booth initiated the BTK inhibitor program at Celera Genomics, Inc. that ultimately became Pharmacyclics, Inc.’s IMBRUVICA® (ibrutinib), the blockbuster drug that changed the paradigm of treatment for many hematological cancers.

Dr. Booth was most recently an adjunct professor at Stanford University School of Medicine. He has over 30 years of experience in the biopharmaceutical industry from executive positions to research and scientific leadership primarily focusing in the areas of oncology, inflammation, and autoimmune disease. He is the co-founder of CuraSen Therapeutics, Inc. where he was previously the Executive Chairman and currently serves as an advisor. He was also the co-founder and CEO of Virobay, Inc. Prior to Virobay, Dr. Booth was an operating partner at TPG Inc. in its biotech fund and served as the Chief Scientific Officer of Celera Genomics. He spent more than a decade in roles of increasing responsibility in research and business development culminating in a Senior Vice President role at Hoffman-La Roche AG (“Roche”). Dr. Booth currently serves on the board of Thryv Therapeutics Inc.; he previously served on the boards of Pharmacyclics, Inc., and CymaBay Inc. He graduated from the University of London with his PhD in biochemistry.